Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol
Kausik K. Ray(Imperial College London), Christie M. Ballantyne(Manpower Demonstration Research Corporation), Harold Bays(Louisville Metabolic and Atherosclerosis Research Center), LeAnne T. Bloedon(Esperion Therapeutics (United States)), Alberico L. Catapano(University of Milan), Paula Robinson(Esperion Therapeutics (United States)), Narendra D. Lalwani(Esperion Therapeutics (United States)), Lulu Ren Sterling(Esperion Therapeutics (United States))
Cited by 794
Related Papers
Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019
|Journal of the American College of Cardiology|2020|11k
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
|New England Journal of Medicine|2017|9.1k
Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel
|European Heart Journal|2017|3.8k
ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)
|European Heart Journal|2011|3.5k
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
|New England Journal of Medicine|2018|3.2k